J Nicholas O'Donnell

17PUBLICATIONS
22CO-AUTHORS
Medical microbiology not elsewhere classifiedMedical infection agents (incl. prions)Microbiology not elsewhere classifiedPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 04, 2026
L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa.

|Apr 24, 2026
Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas-Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model.

|Apr 10, 2026
A novel mechanism of ceftolozane-tazobactam resistance in Pseudomonas aeruginosa mediated by L2 β-lactamase.

Preeti Garai, Sophia H Nozick, Caroline C Jozefczyk

|Aug 31, 2024
Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature.

David A Butler, Nimish Patel, J Nicholas O'Donnell

|Nov 17, 2022
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.

Thomas P Lodise, J Nicholas O'Donnell, Stephen Balevic

|Nov 17, 2022
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.

Thomas P Lodise, J Nicholas O'Donnell, Shruti Raja

Pageof 3

Frequent Collaborators

8 joint publications

Thomas P Lodise

6 joint publications

Nathaniel J Rhodes

4 joint publications

Marc H Scheetz

2 joint publications

Gwendolyn Pais